Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction by Hindricks, Janka






Serum levels of fibroblast growth factor-21 are increased in chronic 








  zur Erlangung des akademischen Grades 
Dr. med. 
an der Medizinischen Fakultät 












angefertigt an der: 










Beschluss über die Verleihung des Doktorgrades vom: 06.10.2015 
  
brought to you by COREView metadata, citation and similar papers at core.ac.uk
provided by Qucosa - Publikationsserver der Universität Leipzig
























Martina Hindricks gewidmet  
	   3	  
Table of Contents 
	  
Table of Contents ..................................................................................................................... 3	  
1. Bibliography ......................................................................................................................... 4	  
2. Introduction .......................................................................................................................... 5	  
2.1 Adipokines – a link between body mass dyregulation and metabolic disturbances ...................... 5	  
2.2 Fibroblast growth factor-21 – a novel adipokine with beneficial properties ................................. 9	  
2.3 Adipokines and renal function ..................................................................................................... 11	  
2.4 FGF-21 and renal function ........................................................................................................... 12	  
3. Methods and Results .......................................................................................................... 14	  
3.1 Research design and Methods ...................................................................................................... 14	  
3.2 Results .......................................................................................................................................... 15	  
4. Publication .......................................................................................................................... 17	  
5. Abstract ............................................................................................................................... 25	  
6. References ........................................................................................................................... 27	  
A. Abbreviations ..................................................................................................................... 32	  
B. Erklärung über die eigenständige Abfassung der Arbeit .............................................. 33	  
C. Erklärung über die Vorbehaltlichkeit der Verfahrenseröffnung zur Verleihung des 
Titels Dr. med. ........................................................................................................................ 34	  
D. Wissenschaftlicher Lebenslauf ............................................................................................. 	  
E. Danksagung ............................................................................................................................ 	  
                                                                                                                  1. Bibliography 




Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal 
dysfunction 
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The progressively increasing prevalence of the Metabolic Syndrome (MetS) has emerged as a 
major global health concern since the MetS is associated with an increased risk for 
cardiovascular morbidity and mortality. Central obesity represents a key feature of the MetS 
and is strongly related to all MetS comorbidities. Dysregulation of adipose tissue-derived 
proteins, so called adipokines, has been implied to partially contribute to these effects. 
Recently, fibroblast growth factor-21 (FGF-21) has been introduced as a novel 
insulin-sensitizing and weight-reducing adipokine with potential therapeutic properties. 
However, data on FGF-21 elimination are rather limited. Therefore, FGF-21 regulation in 
relation to renal function has been investigated in a patient population with chronic kidney 
disease (CKD, study population 1), as well as one with acute kidney impairment (study 
population 2).  
In study population 1 (n = 499), patients were distributed into five CKD subgroups according 
to estimated glomerular filtration rate (eGFR). Median FGF-21 serum concentrations 
progressively increased from CKD stage 1 to stage 5 and highest values of FGF-21 were 
detected in stage 5 (1: 86.4 ng/l; 2: 206.4 ng/l; 3: 289.8 ng/l; 4: 591.3 ng/l; 5: 1918.1 ng/l).	  
Furthermore, eGFR remained the strongest predictor for FGF-21 levels in multivariate 
analysis. For study population 2 (n = 32), blood samples were obtained before elective 
unilateral partial or total nephrectomy, as well as within 30 hours after surgery. In this 
population FGF-21 levels significantly increased after surgery (325.0 ng/l) as compared to 
before surgery (255.5 ng/l). Furthermore, relative changes of FGF-21 were independently and 
positively predicted by relative changes of creatinine in this cohort. 
These results are in accordance with the hypothesis that FGF-21 is eliminated by the kidneys 
and that the extent of kidney dysfunction substantially contributes to serum FGF-21 levels. 
However, additional animal experiments and prospective clinical studies are needed to further 
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2. Introduction 
 
2.1 Adipokines – a link between body mass dyregulation and metabolic disturbances 
In the last decades, dramatic increases in the prevalence of the Metabolic Syndrome (MetS) 
have become a major global health concern. Thus, in the United States of America its 
prevalence increased from 23.1 % to 26.7 % within 12 years.1 Likewise, the prevalence of the 
MetS is beyond 20 % in Germany.2  
The MetS, also known as syndrome X3 and deathly quartet4 was primarily described in the 
late 1920s as a combination of hyperglycemia, hypertension, and gout in patients with a 
predisposition for metabolic disease states.5 In 1947, visceral adiposity has been integrated as 
an additional feature of this new syndrome.6 In 2001, the National Cholesterol Education 
Program (NCEP) has established a clinical definition for the MetS (Table 1) suitable for 
clinical practice and widely used today.7 In accordance with other well accepted definitions 
(World Health Organization,8 International Diabetes Federation9), the NCEP defines insulin 
resistance and central obesity as key aspects of the MetS.  
 
Clinical Identification of the MetS; Diagnosis if  ≥ 3 components are present 
Central obesity,  
given as waist circumference  
     Men 
     Women 
> 102 cm 
>	  88	  cm	  
Triglycerides ≥ 1.7 mmol/L 
High density lipoprotein cholesterol  
     Men  
     Women 
< 1.04 mmol/L 
< 1.30 mmol/L 
Blood pressure ≥130/ ≥ 85 mmHg 
Fasting plasma glucose ≥ 6.1 mmol/L 
Table 1. Clinical criteria for the diagnosis of the MetS adapted from the executive 
Summary of the Third Report of the NCEP Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults7  
 
Onset of the MetS is associated with an increased risk for cardiovascular disease (CVD) 
including myocardial infarction and stroke10,11 and subsequently an increase in cardiovascular 
mortality.12 
Out of all components, central obesity is most strongly associated with the MetS13 and weight 
loss therapy remains the primary treatment for the MetS7 as it improves all MetS aspects as 
well as cardiovascular outcomes.14,15 Central obesity is defined as indicated in Table 116 and 
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Adipose tissue mass mainly consists of adipocytes but also pre-adipocytes, endothelial cells, 
and immune cells, as well as intercellular matrix.18 In general, adipose tissue has significant 
impact on energy and glucose homeostasis. Thus, the presence of insulin leads to enhanced 
glucose uptake whereas lipolytic hormones stimulate the release of fatty acids in starvation 
periods.  
Notably, adipose tissue has also been identified as an important endocrine regulator in the last 
decades, providing a potential link between adipose tissue mass dysregulation and the 
occurrence of the MetS. In this context, adipocytokines or adipokines are adipose tissue-
secreted proteins with numerous functions in human metabolic processes. Thus, adipokines 
are involved in glucose homeostasis,19 insulin secretion,20 and the regulation of food intake.21 
Furthermore, dysregulation of adipokines is present in diseases affecting these processes e.g. 
type 2 diabetes mellitus (T2DM), insulin resistance, and obesity.22 Important adipokines 
relevant to the present study will be introduced in more details within the next paragraphs. 
 
The beginning of a new understanding of adipose tissue function has been marked by the 
discovery of the adipokine leptin. As early as 1950, Ingalls and co-workers introduced a then 
unknown gene mutation in mice which is associated with a morbidly obese phenotype: the ob 
gene.23 Weight gain in these mice is associated with massive overeating and leads to three 
times the body weight of healthy animals. In 1994 Zhang and co-workers reported the 
detection of a 16 kDa protein encoded by the ob gene and expressed almost exclusively in 
adipose tissue.24 The protein received the name leptin after the Greek word leptos, meaning 
thin. The leptin receptor has subsequently been detected in the choroid plexus of rodents25 and 
in high concentrations in the hypothalamus26 but it is also present in different tissues 
throughout the body.27–29 Soluble leptin binds to its receptor in the hypothalamic region and 
leads to a reduction of neuropeptide Y (NPY) mRNA expression26 a protein responsible for 
appetite and regulation of food intake.30 In health, leptin release from adipocytes is controlled 
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Regulation of leptin release from adipose tissue in health 
 
Figure 1. Simplified depiction of feedback processes for leptin release from adipocytes: 
In the fed state, increased leptin secretion leads to reduced NPY release. Subsequently, 
less food is consumed. In the fasted state decreased leptin concentrations lead to 
enhanced NPY release with increased food consumption. 
  
These feedback mechanisms are extensively responsible for the balance between energy 
intake and energy expenditure. Hence, mutations of the ob gene result in weight gain and 
metabolic disturbances e.g, hyperglycemia and hyperinsulinemia in rodents.24 Leptin 
administration leads to decreases in body weight and ameliorates glucose imbalance in 
leptin-deficient ob/ob, mice.31 Paradoxically, ob/ob mice display limited progression of 
atherosclerosis32, whereas leptin administration results in worsening of atherosclerotic 
lesions.32 Apart from facets of the MetS, leptin is also involved in various processes including 
fertility23 and bone metabolism.33 
Along with the growing rates of obesity and T2DM, a lot of hope has been put into leptin as a 
therapeutic agent for facets of the MetS, especially due to the positive results of leptin 
administration on body weight of leptin-deficient rodents.34 In patients with lipodystrophy, a 
disorder characterized by leptin-deficiency, 4 months of subcutaneous leptin treatment in fact 
leads to improved lipid profile and reduced need of antidiabetic therapy.35 However, obese 
patients exhibit increased leptin gene expression in adipose tissue as compared to non-obese 
patients and levels of the adipokine highly correlate with body mass index.36 Furthermore, 
leptin levels predict worsening of the MetS independent from obesity.37 It is, therefore, 
postulated that obesity and other metabolic disturbances induce a leptin-resistant state 
comparable to insulin resistance in T2DM. Nonetheless, the pathophysiology behind the onset 
of leptin resistance remains unclear so far.  
 
Another important adipokine closely linked to the MetS is adiponectin. Two years after the 
discovery of leptin, Maeda and co-workers demonstrated another gene almost exclusively and 
abundantly expressed in adipose tissue: the apM1 gene.38 Gene product is a 224 amino-acid, 
protein with similarities to collagen and complement 1q: adiponectin (apM1, AdipoQ).38 The 
	  
NPY Leptin 	   	   Food intake 	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adipokine binds to two receptors, AdipoR1 and AdipoR2 with different expression patterns in 
mice and humans. AdipR1 is found ubiquitously whereas AdipqR2 is predominantly 
expressed in the liver.39 Binding of the adipokine to its receptor leads to enhancements in 
fatty acid oxidation in skeletal muscle and liver cells, as well as stimulation of glucose uptake 
in skeletal muscle cells.39 Therefore, adiponectin is considered to be an adipokine with 
beneficial effects on glucose and lipid metabolism. In mouse 3T3-L1 preadipocytes, 
adiponectin mRNA expression increases considerably during differentiation and adiponectin 
stimulates adipocyte cell proliferation.40 Transgenic mice with adiponectin overexpression 
exhibit increased energy expenditure, a beneficial lipid profile, low blood glucose levels, and 
considerable decreases in adipocyte differentiation.41 In obese mice, levels of adiponectin are 
extensively decreased as compared to lean controls.42 Apart from obesity, plasma adiponectin 
levels are significantly reduced in various metabolic disturbances in rodents and primates. 
Adiponectin knockout mice display diet-induced insulin resistance43 and serum levels of the 
adipokine correlate inversely with the degree of insulin resistance in monkeys.44 In 
concordance with these results in animals, adiponectin concentrations are considerably 
decreased in humans with facets of the MetS as compared to normal-weight subjects.42 
Furthermore, plasma adiponectin levels are reduced in diabetic patients as compared to 
healthy controls.45 Moreover, adiponectin concentrations are an independent predictor for the 
occurrence of the MetS46 and are negatively associated with blood pressure in 21,000 healthy 
subjects.47 
Since CVD represents the leading cause for MetS-associated morbidity and mortality, the role 
of adiponectin in CVD has been subject to through investigations by different groups. 
Interestingly, adiponectin has anti-atherogenic effects.48 Mechanisms for these beneficial 
effects of adiponectin include anti-inflammatory properties and decreased tumor necrosis 
factor (TNF) α-induced monocyte adhesion.48 Since patients with CVD generally exhibit low 
levels of adiponectin48, hypoadiponectaemia in the MetS might contribute to increased risk 
for cardiovascular events. 
  
Apart from adiponectin, chemerin represents an additional adipokine with metabolic, as well 
as chemotactic, properties. Chemerin was primarily discovered in the 1990’s as a product of 
the tazarotene-induced gene 1 or retinoid acid receptor responder 2, a gene responsive to 
retinoid acid treatment in psoriasis, an inflammatory skin disease.49 The adipokine is ligand to 
three different receptors: chemokine receptor-like 1 (CMKLR1), chemokine receptor-like 2 
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throughout the body. CMKLR1 is predominantly expressed in white adipose tissue of mice, 
whereas high concentrations of CCRL2 and GPCR1 are found in rodent skeletal muscle 
cells.50 While CCRL2 and GPCR1 function remains to be elucidated, binding of chemerin to 
the CMKLR1 stimulates migration of macrophages and immature dendritic cells to sites of 
injury in vitro.51 Furthermore, similar to adiponectin, chemerin is induced during adipocyte 
differentiation in vitro.52 Moreover, incubation of 3T3-L1 preadipocytes with chemerin 
significantly increases insulin-stimulated glucose uptake.53 Extensive studies in leptin-
deficient ob/ob and leptin receptor-deficient db/db mice, which serve as models for obesity 
and T2DM, demonstrate significant increases in total chemerin concentration and decreases in 
CMKLR1 expression in white adipose tissue as compared to healthy mice.50 Furthermore in 
contrast to in vitro studies, chemerin administration results in aggravation of glucose 
intolerance by decreasing glucose uptake and insulin secretion in obese, as well as diabetic, 
mice.50  
Chemerin concentrations correlate positively with markers of inflammation, e.g. C- reactive 
protein (CRP), interleukin-6 (IL-6). and TNF-α in human subjects.54 Circulating chemerin is 
significantly and positively associated with multiple facets of the MetS.54 However, chemerin 
regulation in insulin resistance, as well as CVD, in humans remains controversial. Thus, 
Spiroglou and co-workers reveal a positive association between chemerin levels and coronary 
atherosclerosis whereas no association is seen in another study.54,55 Furthermore upregulation 
and no regulation of the adipokine in T2DM have been reported.56,57 
 
2.2 Fibroblast growth factor-21 – a novel adipokine with beneficial properties 
The fibroblast growth factor (FGF) family is a group of proteins with various effects on 
human and animal cells including, angiogenesis, embryogenesis and regulation of cell 
survival.58 With first recognition in 197459, to date the FGF family consists of 22 members, 
which can be further subcategorized into three groups: intracellular, paracrine, and hormone-
like subfamily.60 Extensive research during the last decades is only beginning to elucidate the 
role of the hormone-like subfamily members, e.g. FGF-15, FGF-21 and FGF-23, in human 
metabolic processes.  
FGF-21 is a 181 amino acid protein which binds to the FGF receptor, a transmembrane 
tyrosine kinase, in a β-Klotho dependent manner.60 FGF-21 was initially identified in liver 
and thymus tissue of mouse embryos by Nishimura and co-workers in 2000.61 Soon after, 
adipose tissue has been revealed as an additional source of FGF-21 expression.62 Research on 
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expression during adipogenesis.62 Furthermore, FGF-21 mediates insulin-independent 
stimulation of glucose uptake in differentiated adipocytes.63 In more detail, binding of the 
adipokine to the FGF receptor induces an intracellular signal cascade leading to increased 
glucose transporter (GLUT)-1 gene expression.64 Subsequent translocation of GLUT-1 
generates increased glucose uptake in adipocytes.   
In animal models, FGF-21 mRNA expression increases in adipose tissue and liver of 
diet-induced obese mice and treatment with FGF-21 reduces body weight and ameliorates 
insulin resistance in these mice.65,66 Administration of FGF-21 to diabetic primates leads to 
improved serum glucose and lipid profiles.67  
It is apparent that due to its beneficial effects on insulin resistance, central obesity, and serum 
lipids in rodents, FGF-21 functions as a potential pharmacological target for the treatment of 
these metabolic disturbances seen in the MetS. Therefore, over the past years, several studies 
have focused on FGF-21 regulation in human subjects with components of the MetS. In this 
context, data of FGF-21 serum levels in patients with T2DM, an insulin resistant state, reveal 
significant upregulation of the adipokine as compared to healthy controls.68,69 Furthermore, 
two independent studies show elevated FGF-21 levels in obese as compared to normal-weight 
subjects.62,70 Notably, FGF-21 independently predicts the occurrence of the MetS in a 
longitudinal study with 440 patients.71 Furthermore, Zhang and co-workers demonstrate a 
progressive increase in FGF-21 levels with increasing number of MetS components.62 
The paradoxical increase of the beneficial adipokine FGF-21 in humans with facets of the 
MetS is subject of ongoing investigations. It appears that FGF-21 resistance in the MetS, 
similar to leptin resistance, is at least partially accountable for this upregulation.. Additionally 
and alternatively, FGF-21 induction might be a compensatory response to limit the adverse 
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2.3 Adipokines and renal function 
The kidneys are substantially involved in the regulation of various processes in humans. 
Apart from adjusting blood pressure, as well as maintaining acid-base and fluid balance, 
filtration of blood followed by excretion of waste products is another important task.  
According to the Kidney Disease: Improving Global Outcomes criteria, chronic kidney 
disease (CKD) is defined as abnormalities of kidney structure or function, present for more 
than three months, alongside implications for health. The deterioration of renal function 
substantially contributes to an increased risk for CVD and premature death.72 Several features 
of patients with MetS, such as T2DM and hypertension73 have long been held accountable for 
these adverse outcomes in patients with CKD. However, recent studies suggest additional 
pathophysiological mechanisms responsible for the increase in cardiovascular events in 
patients with impaired renal function. It has been demonstrated, that diminished elimination 
of adipokines in patients with kidney function impairment significantly adds to the occurrence 
of CVD.74 Therefore, adipokine regulation in relation to renal function has been subject to 
profound investigations over the last years.  
In this context, Cumin and co-workers have been among the first groups to provide 
substantial evidence that leptin is eliminated by the kidneys by performing bilateral 
nephrectomy as compared to sham operation in rats. In more detail, levels of the adipokine 
spike significantly and immediately after the surgery and progressively increase within the 
next 48 h. Gel electrophoresis further shows that leptin levels are decreased in venous as 
compared to arterial renal blood and extraction rate is calculated at 45%. However, only small 
amounts of leptin are found in urine suggesting renal metabolization rather than excretion.75 
In humans, Sharma and co-workers have quantified leptin levels in human aortic and renal 
vein blood. Leptin concentrations are decreased by 12 % in renal vein as compared to aortic 
blood in healthy patients whereas leptin levels remain constant in patients with mild to 
moderate stages of CKD. Moreover, serum levels of the adipokine are 4.5 fold increased in a 
second cohort with end-stage renal disease (ESRD).76 Notably, leptin serum concentrations 
significantly and negatively correlate with glomerular filtration rate.77 Since leptin is 
considerably contributing to worsening of atherosclerosis32, it has been suggested that 
hyperleptinaemia seen in patients with deteriorating renal function should be subject to 
therapeutic intervention.78 In contrast, adiponectin is associated with a beneficial metabolic 
and cardiovascular profile.48 Animal studies of renal function-associated adiponectin 
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nephrectomy. Furthermore, injection of wild type plasma to adiponectin knockout mice 
reveals lower adiponectin clearance rates in nephrectomized as compared to sham-operated 
mice, again indicating renal elimination of the adipokine.79 In humans, deterioration of renal 
function results in progressive elevation of serum adiponectin levels and patients with ESRD 
receiving kidney transplants exhibit lower levels of adiponectin after as compared to before 
transplantation.80 Since a beneficial role of the adipokine in CVD is implied, several studies 
focus on hyperadiponectaemia in renal disease in relation to cardiovascular events. However, 
data remain controversial. Thus, Becker and co-workers demonstrate low adiponectin levels 
as a risk factor for cardiovascular events in a prospective study of patients with renal 
dysfunction.81 In contrast, a decreased risk for cardiovascular mortality is shown in patients 
with low adiponectin concentrations in another study.82 In accordance with studies on leptin 
and adiponectin, chemerin serum concentrations are also upregulated in humans with 
impaired renal function. Recently, our group has demonstrated significant upregulation of the 
adipokine in patients undergoing chronic hemodialysis as compared to healthy controls.83 In 
this study, estimated glomerular filtration rate (eGFR) remains an independent predictor for 
circulating chemerin in ESRD patients.83 In accordance with our findings, Yamamoto and co-
workers also reveal a negative correlation between chemerin and eGFR in a study population 
of 252 patient with CKD stage 5.84 Notably in a 5-year follow-up, high chemerin levels at 
baseline have predicted a better overall survival.84 In addition, ESRD patients exhibit 30% 
higher chemerin serum levels before as compared to after receiving kidney transplant.85 
2.4 FGF-21 and renal function 
In contrast to these well-described adipokines, i.e. leptin, adiponectin, and chemerin, data on 
FGF-21 regulation in relation to renal function are particularly limited. Thus, our group has 
been the first to describe an association between the adipokine and renal function in a small 
study population of patients undergoing chronic hemodialysis (n = 120).86 Data on these 
patients with extensively diminished renal function revealed significant increases in FGF-21 
levels in comparison with healthy controls. Furthermore, eGFR negatively predicts levels of 
the adipokine.86 In agreement with these findings, Lin and co-workers demonstrate increased 
FGF-21 serum concentrations in a small patient population with severe as compared to mild 
CKD.87 However, patient numbers in these studies have been rather small and none of the 
studies covered all stages of CKD. Furthermore, to the best of our knowledge, no data are 
available on FGF-21 regulation in patients with acute kidney injury. To address these 
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covering CKD stages 1 to 5. Furthermore, we measured FGF-21 levels in 32 patients 
undergoing elective partial or total unilateral nephrectomy. Moreover, in both study 
populations, FGF-21 levels were correlated with biochemical and anthropometric measures of 
renal function, inflammation, glucose metabolism, and lipid metabolism. We hypothesized 
that: 
1. FGF-21 levels progressively increase with increasing CKD stage in humans. 
2. FGF-21 serum concentrations increase in patients with acute kidney injury. 
	    
3. Methods and Results 
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3. Methods and Results 
 
3.1 Research design and Methods 
To address the hypotheses summarized in 2.4. two different study populations were recruited. 
Study population 1 consisted of 499 patients (men: n = 280; women: n = 219) with varying 
degrees of CKD (1: n = 48; 2: n = 88; 3: n = 128; 4: n = 54; 5: n = 181). Stages of CKD were 
defined according to the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines. 
Thorough clinical examination and questionnaire on past medical history were conducted 
prior to the collection of blood samples under fasting conditions (> 8 hours after last meal). In 
patients on hemodialysis, blood samples were taken before hemodialysis started.  
Study population 2 included 32 patients (men: n = 26; women: n = 6) from the Department of 
Urology, University of Leipzig, undergoing partial or total unilateral nephrectomy. Again, 
patients received a thorough clinical examination and a questionnaire on past medical history 
was completed. Blood samples under fasting conditions were taken prior to surgery, as well 
as within 30 hours after surgery.  
In both study populations, biochemical parameters were measured by the Institut für 
Labormedizin, Klinische Chemie und Molekulare Diagnostik, Leipzig. Levels of adiponectin, 
leptin, and FGF-21 were quantified by commercial enzyme-linked immunoabsorbant assays. 
Written informed consent was obtained from all patients. Statistical analyses were conducted 
using SPSS software version 20.0.  
3. Methods and Results 
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3.2 Results 
In study population 1, median FGF-21 serum levels progressively increased from CKD stage 
1 to CKD stage 5 (1: 86.4 ng/l; 2: 206.4 ng/l; 3: 289.8 ng/l; 4: 591.3 ng/l; 5: 1918.1 ng/l). 
Significant increases are depicted in Figure 2.     
 
 
Figure 2. Median values (interquartile range) of FGF-21 serum concentrations in 
relation to CKD stage according to the KDOQI guidelines (n = 499). * indicates 
statistical significance (p < 0.05). 
 
Furthermore, patients with diabetes mellitus exhibited significantly higher values of FGF-21 
(619.7 ng/l) as compared to patients without diabetes (437.1 ng/l) (p = 0.003). Moreover, men 
(552.1 ng/l) had significantly higher levels of FGF-21 as compared to women (441.2 ng/l) (p 
= 0.020). Univariate correlation method revealed significant and positive associations 
between FGF-21 on one hand and age, waist-to-hip ratio (WHR), waist-to-height ratio, serum 
creatinine, triglycerides, high sensitivity (hs)CRP, hsIL-6, leptin, and adiponectin on the other 
hand. Furthermore, a significant and negative correlation was present between FGF-21 levels 
and diastolic blood pressure, eGFR, fasting glucose, cholesterol, HDL cholesterol, and low-
density lipoprotein (LDL) cholesterol. In multivariate regression analysis, the renal marker 
eGFR remained the strongest negative predictor for FGF-21 levels. Furthermore, a negative
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 association was observed with LDL cholesterol whereas a positive association between 
FGF-21 levels on the one hand and WHR, triglycerides, and adiponectin on the other hand 
persisted in multiple regression analysis.  
In study population 2, Median FGF-21 levels significantly increased in patients after 
unilateral partial or total nephrectomy (325.0 ng/l) as compared to before surgery (255.5 ng/l) 
(p < 0.05) (Figure 3).   
 
 
Figure 3. Median (interquartile range) FGF-21 serum concentrations in patients before 
and after unilateral partial or total nephrectomy (n = 32). * indicates statistical 
significance (p < 0.05) assessed after Wilcoxon signed-rank test.  
 
Furthermore, creatinine, hsCRP and hsIL-6 significantly increased whereas eGFR, levels of 
triglycerides, cholesterol, HDL and LDL cholesterol and adiponectin significantly decreased 
after surgery. Moreover, relative changes (post-to-presurgery) of FGF-21 serum 
concentrations correlated negatively with relative changes of eGFR and positively with 
relative changes of creatinine in univariate analysis. In addition, relative changes of creatinine 
remained a strong predictor for relative changes of FGF-21 levels in multivariate analysis 
even after adjustment for age and gender (p < 0.001).  
These results support the hypothesis that FGF-21 levels in humans are closely linked to renal 
function, assessed as eGFR, in patients with CKD, as well as acute renal dysfunction. 
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O R I G I N A L A R T I C L E
Serum levels of fibroblast growth factor-21 are increased in
chronic and acute renal dysfunction
Janka Hindricks*,†,1, Thomas Ebert*,†,1, Anette Bachmann*, Susan Kralisch*,†, Ulrike L€ossner*,†,
J€urgen Kratzsch‡, Jens-Uwe Stolzenburg§, Anja Dietel§, Joachim Beige¶, Matthias Anders**, Ingolf Bast**,
Matthias Bl€uher*, Michael Stumvoll* and Mathias Fasshauer*,†
*Department of Endocrinology and Nephrology, University of Leipzig, †IFB Adiposity Diseases, Leipzig University Medical Center
‡Institute of Laboratory Medicine, University of Leipzig, §Department of Urology, University of Leipzig, ¶Division of Nephrology
and KfH Renal Unit, Hospital St. Georg and **Outpatient Nephrology Care Units, Leipzig, Germany
Summary
Objective Fibroblast growth factor (FGF)-21 has recently been
introduced as a circulating adipokine which reverses insulin
resistance and obesity in rodents. In this study, regulation of
FGF-21 in renal dysfunction was elucidated in both chronic
kidney disease (CKD) and acute kidney dysfunction (AKD).
Study design and methods Serum concentrations of total
FGF-21 were quantified by enzyme-linked immunosorbent assay
in 499 patients with CKD stages 1–5 (study population 1).
Furthermore, total FGF-21 was determined before and within
30 h after unilateral nephrectomy, a model of AKD, in 32 patients
(study population 2). FGF-21 levels were correlated to anthropo-
metric and biochemical parameters of renal function, glucose and
lipid metabolism, as well as inflammation, in both studies.
Results In study population 1, median [interquartile range]
circulating FGF-21 adjusted for age, gender and body mass index
was significantly different between CKD stages with highest values
detectable in stage 5 (stage 1: 86!4 [132!9]; 2: 206!4 [223!1]; 3:
289!8 [409!3]; 4: 591!3 [789!0]; 5: 1918!1 [4157!0] ng/l). Further-
more, estimated glomerular filtration rate remained a strong inde-
pendent and negative predictor of FGF-21. In study population 2,
FGF-21 increased significantly postsurgically (325!0 [984!0] ng/l)
as compared to presurgical values (255!5 [243!0] ng/l). Further-
more, relative changes of FGF-21 were independently and posi-
tively predicted by relative changes of creatinine.
Conclusions We demonstrate that circulating FGF-21 is
increased in both CKD and AKD. Our results suggest renal
excretion as a major route for FGF-21 elimination. The patho-
physiological significance of these findings needs to be elucidated
in more detail.
(Received 16 August 2013; returned for revision 11 September
2013; finally revised 2 December 2013; accepted 2 December 2013)
Introduction
Various adipocyte-secreted factors, so-called adipokines, contrib-
ute to facets of the metabolic syndrome (MetS). Thus, the
adipokine adiponectin induces a beneficial metabolic profile.1 In
contrast, the appetite-suppressive adipokine leptin is upregulated
in obesity1 and associated with an increased risk of cardiovascu-
lar disease (CVD).1 Furthermore, the adipokine interleukin-6
induces insulin resistance and is associated with risk factors for
CVD in humans.1
Recently, fibroblast growth factor (FGF)-21, a member of the
FGF family, has been introduced as an adipokine stimulating
glucose uptake in adipocytes2 and increasing insulin sensitivity
in rodents.3 However, the adipokine is paradoxically upregulated
in various metabolic disease states in human subjects.4,5 Thus,
Lin et al.4 have revealed upregulation of FGF-21 in 135 patients
with coronary heart disease as compared to healthy controls.
Moreover, Chavez et al.5 demonstrated increased FGF-21 serum
levels in patients with type 2 diabetes mellitus as compared to
healthy controls. Taking these studies into account, FGF-21
appears to be an adipokine with multiple beneficial metabolic
effects in rodents. However, exact mechanisms of FGF-21 upreg-
ulation in human metabolic disease remain unclear.
In contrast to these extensive studies in human metabolic dis-
ease, elimination of FGF-21 has not been studied in detail so
far. Most importantly, previous studies on FGF-21 and renal
function6–8 show the following limitations: none of the studies
(i) included >250 patients; (ii) covered the whole spectrum of
renal dysfunction ranging from CKD stages 1–5 comprehen-
sively; and (iii) elucidated the role of acute decreases in kidney
function on FGF-21 serum levels. To address these issues and to
more definitely define the role of the kidney in FGF-21 elimina-
tion, we quantified FGF-21 serum concentrations in 499 patients
covering the whole spectrum of CKD (study population 1).
Correspondence: Thomas Ebert, Department of Endocrinology and
Nephrology, University of Leipzig, Liebigstr. 20, 04103 Leipzig, Germany.
Tel.: 49 341 9713380; Fax: 49 341 9713389; E-mail: thomas.ebert@
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Furthermore, we evaluated for the first time FGF-21 serum levels
in 32 patients before and after unilateral partial or total nephrec-
tomy (study population 2). Moreover, we correlated the adipo-
kine to clinical and biochemical parameters of renal function,
glucose and lipid metabolism, as well as inflammation.
We hypothesized that FGF-21 serum concentrations (i)
increase with deteriorating renal function in CKD (study popu-
lation 1) and (ii) are increased in acute renal dysfunction after
nephrectomy (study population 2).
Research design and methods
Subjects
Study population 1. For this cross-sectional study, 532 patients
(men: n = 305; women: n = 227) were recruited between 2006
and 2010 by the Department of Endocrinology and Nephrology,
University of Leipzig and from three outpatient Nephrology
Care Units (Hospital St. Georg, Division of Nephrology, KfH
Renal Unit, 04129 Leipzig; outpatient Nephrology Care Units,
04107 and 04178 Leipzig) as described in detail recently.9 Prior
to analyses, all patients on peroxisome proliferator-activated
receptor (PPAR)a- and PPARc-agonists were excluded, and 499
patients remained in the study. Study participants underwent a
thorough examination including anthropometric measures of
obesity (waist and hip circumference, height, body mass index
[BMI], waist-to-hip ratio [WHR] and waist-to-height ratio
[WHtR]), hypertension and a standardized questionnaire on
past medical history. Furthermore, blood samples were drawn
after an overnight fast at the respective care units. In
haemodialysis patients, blood samples were taken right before
haemodialysis started. Age of the study population was between
19 and 92 years, and BMI ranged from 14!3 to 49!0 kg/m2.
Estimated glomerular filtration rate (eGFR) was calculated
according to the Modification of Diet in Renal Disease (MDRD)
formula10, and all patients were classified into chronic kidney
disease (CKD) stages 1–5 according to the National Kidney
Foundation – Kidney Disease Outcomes Quality Initiative
(KDOQI) guidelines.11 Homeostasis model assessment of insulin
resistance (HOMA-IR) was determined as described.12
Study population 2. For this longitudinal cohort, 32 patients
(men: n = 26; women: n = 6) undergoing elective partial or
total unilateral nephrectomy were recruited by the Department
of Urology and the Department of Endocrinology and
Nephrology, University of Leipzig. Recent studies convincingly
demonstrated that these patients serve as a model for acute
kidney dysfunction (AKD).13,14 The study design was described
recently.15 Indications for surgery included renal carcinoma,
renal shrinkage and renal cysts. The following inclusion and
exclusion criteria were applied: inclusion criteria, age between 18
and 80 years; and exclusion criteria, haemodialysis, hereditary
renal cysts, glomerulonephritis and generalized inflammation.
Blood samples under fasting conditions were obtained shortly
before renal surgery (median [interquartile range] time of the
first blood sampling 08:15 [2:00] AM), as well as within 30 h
after surgery (05:00 [0:22] AM). Age of the study population
ranged from 22 to 78 years and BMI from 18!2 to 37!0 kg/m2.
Anthropometric data (BMI, WHR and WHtR), as well as
HOMA-IR, were assessed as described previously. For this
population, eGFR was calculated using the Chronic Kidney
Disease Epidemiology Collaboration formula including four
parameters (serum creatinine, gender, race and age).16
Both studies were approved by the local Ethics Committee,
and written informed consent was obtained from all patients
before taking part in the studies.
Assays
Serum concentrations of total FGF-21 were determined with a
commercial enzyme-linked immunosorbent assay (ELISA) from
Biovendor (Modrice, Czech Republic). Intra- and interassay
coefficients were <4!1% and 3!9%, respectively. Sensitivity was
7 ng/l, and the ELISA was specific for human FGF-21 with no
cross-reactivity with human FGF-19 and human FGF-23. Nor-
mal median FGF-21 levels for patients beyond 50 years of age
were given by the manufacturer as follows: female 222!2 ng/l
and male 237!4 ng/l. Leptin was quantified with a high-sensitiv-
ity ELISA from Mediagnost (Reutlingen, Germany). Intra- and
interassay coefficients were <4!4% and 7!5%, respectively. Sensi-
tivity was 0!2 lg/l, and the ELISA was specific for human leptin
with no cross-reactivity to other proteins such as insulin or
insulin-like growth factor-1. Normal median leptin levels for
subjects with a BMI of 25 kg/m2 were given by the manufacturer
as follows: female 11!9 lg/l and male 3!18 lg/l. Total adiponec-
tin was determined with an ELISA from Mediagnost (Reutlin-
gen, Germany). Intra- and interassay coefficients were <4!7%
and 6!7%, respectively. Sensitivity was 0!6 lg/l, and the ELISA
was specific for human adiponectin with no cross-reactivity to
other species. Normal median adiponectin levels were given by
the manufacturer as follows: female 9!1 mg/l and male 6!1 mg/l.
Total rather than other molecular isoforms of adiponectin, for
example high molecular weight adiponectin, was quantified in
this study as most analyses in the literature concerning adipo-
nectin and metabolic disease have been performed with assays
quantifying total protein.17,18 In all patients, serum concentra-
tions of high-sensitivity interleukin-6 (hsIL-6) were determined
with a commercial ELISA from R&D Systems (Minneapolis,
MN, USA) according to the manufacturer’s instructions. Intra-
and interassay coefficients were less than 4!2% and 6!4%, respec-
tively. Sensitivity was 0!7 ng/l, and the ELISA was specific for
human IL-6 with no cross-reactivity to other species and inter-
leukins. Serum creatinine, fasting glucose (FG), fasting insulin
(FI), triglycerides (TG), cholesterol, high-density lipoprotein
(HDL) cholesterol, low-density lipoprotein (LDL) cholesterol
and high-sensitivity C-reactive protein (hsCRP) were measured
in a certified laboratory by standard methods.
Statistical analysis
SPSS software version 20.0 (IBM, Armonk, NY, USA) was used
for all statistical analyses.
© 2013 John Wiley & Sons Ltd
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In study population 1, overall group differences for continu-
ous parameters were assessed by Kruskal–Wallis test followed by
post-hoc analysis with prior adjustment for age, gender and BMI.
Univariate correlations were assessed by nonparametric Spear-
man’s rank correlation method. Furthermore, multivariate linear
regression analysis was performed. Prior to the multivariate
analysis, distribution of continuous variables was tested for nor-
mality using the Shapiro–Wilk-test, and non-normally distrib-
uted parameters were logarithmically transformed.
In study population 2, differences in FGF-21 serum concen-
trations and other laboratory parameters before and after renal
surgery were assessed by Wilcoxon signed-rank test for related
samples. Furthermore, relative changes (postsurgical-to-presurgi-
cal ratios) were calculated for all laboratory parameters as
follows: parameter (ratio) = parameterpostsurgery/parameter
presurgery similar to other studies.
19 Univariate correlation analysis
was performed by Spearman’s rank correlation method using
these relative changes (ratios). Afterwards, multivariate linear
regression analysis was performed as described previously. In all
multivariate linear analyses, parameters that correlated signifi-
cantly with FGF-21 in univariate analysis were included. For
covariates, for example creatinine and eGFR, the parameter with
the strongest univariate correlation was included in the multi-
variate model. Furthermore, age and gender were included in all
multivariate analyses. A P-value of <0!05 was considered as
statistically significant in all analyses.
Results
Study population 1
FGF-21 serum concentrations are increased in patients with
CKD. The clinical characteristics of the five CKD subgroups
studied are summarized in Table 1. Median [interquartile range]
FGF-21 levels were 512!7 [1204!1] ng/l in the total study
population. FGF-21 levels were significantly different between
the five CKD stages (P < 0!001). Serum FGF-21 concentrations
increased with deteriorating renal function, and highest values
were seen in CKD stage 5 (Table 1). When patients were
divided according to diabetes mellitus status, circulating median
[interquartile range] FGF-21 was significantly higher in patients
with diabetes mellitus (619!7 [1696!8] ng/l) as compared to
nondiabetic subjects (437!1 [1147!3] ng/l) (P = 0!003). In
contrast, FGF-21 was not significantly different between
overweight/obese patients (476!6 [1094!5] ng/l) as compared to
lean subjects (555!2 [1738!0] ng/l) (P = 0!492). Moreover, FGF-
21 levels were significantly higher in men (552!1 [1570!1] ng/l)
as compared to women (441!2 [797!1] ng/l) (P = 0!020). In
Table 1. Baseline characteristics of the study population 1, divided into five stages of CKD
Stage 1 2 3 4 5
N 48 88 128 54 181
FGF-21 (ng/l) 86!4 (132!9) 206!4 (223!1) 289!8 (409!3)1 591!3 (789!0)1,2,3 1918!1 (4157!0)1,2,3,4
Age (years) 55!3 (16!3) 64!7 (14!7) 72!8 (15!2)1,2 76!7 (14!1)1,2 66!3 (21!1)1,3,4
Gender (m/f) 25/23 37/51 82/46 28/26 108/73
Diabetes (%) 20 (42) 29 (33) 47 (37) 16 (30) 66 (37)
BMI (kg/m2) 26!6 (6!1) 28!5 (5!8) 27!5 (4!4) 26!5 (5!1)2 26!1 (6!8)2
SBP (mmHg) 130 (20) 130 (27) 135 (25) 140 (24) 130 (25)4
DBP (mmHg) 80 (20) 80 (20) 80 (17) 80 (20) 75 (15)2,3,4
WHR 0!93 (0!09) 0!91 (0!12) 0!95 (0!09) 0!96 (0!11) 0!97 (0!10)1,2,3
WHtR 0!56 (0!10) 0!59 (0!12) 0!60 (0!09) 0!59 (0!09) 0!61 (0!13)1,2,3
Creatinine (lmol/l) 59 (19) 80 (23) 139 (43)1,2 217 (70)1,2,3 702 (392)1,2,3,4
eGFR (ml/min/1!73 m²) 105!2 (12!6) 74!7 (13!5) 44!1 (14!3)1,2 24!5 (5!7)1,2,3 6!7 (5!1)1,2,3,4
FG (mmol/l) 5!5 (2!1) 5!5 (1!4) 5!7 (1!9) 5!7 (1!4) 4!8 (1!8)1,2,3,4
FI (pmol/l) 69!1 (68!5) 67!3 (63!5) 75!6 (94!4) 75!6 (53!7) 44!6 (67!3)3,4
HOMA-IR 2!3 (2!8) 2!3 (2!8) 2!6 (3!7) 2!8 (2!5) 1!4 (2!3)3,4
TG (mmol/l) 1!05 (0!68) 1!53 (0!92)1 1!5 (1!21)1 1!63 (1!28)1 1!62 (0!98)1
Cholesterol (mmol/l) 5!3 (1!5) 5!4 (1!3) 5!3 (1!6) 6!2 (2!4) 4!6 (1!7)1,2,3,4
HDL cholesterol (mmol/l) 1!4 (0!6) 1!4 (0!4) 1!3 (0!5) 1!4 (0!9) 1!1 (0!5)1,2,3,4
LDL cholesterol (mmol/l) 3!3 (1!4) 3!3 (1!3) 3!0 (1!5) 3!1 (1!9) 2!6 (1!3)1,2,3,4
hsCRP (mg/l) 1!9 (5!1) 2!6 (3!7) 2!6 (3!3) 3!4 (5!0) 4!4 (9!6)1,2,3
hsIL-6 (ng/l) 1!5 (1!6) 1!8 (1!1) 2!3 (1!7) 3!1 (3!7)1,2,3 5!0 (5!5)1,2,3,4
Leptin (lg/l) 11!5 (15!1) 18!3 (26!0) 20!3 (36!0)1 21!9 (38!7)1,2 19!4 (48!1)1,2
Adiponectin (mg/l) 5!9 (6!5) 6!6 (6!9) 9!0 (8!6) 10!9 (11!0)1,2 15!5 (13!8)1,2,3
BMI, body mass index; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FG, fasting glucose;
FGF-21, fibroblast growth factor-21; FI, fasting insulin; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance;
hsCRP, high-sensitivity C-reactive protein; hsIL-6, high-sensitivity interleukin-6; LDL, low-density lipoprotein; SBP, systolic blood pressure; TG, trigly-
cerides; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio. Values for median (interquartile range) or total number (percentage) are shown. Con-
tinuous parameters were adjusted for age, gender and BMI and analysed by Kruskal–Wallis test followed by post-hoc analysis. Numbers in superscript
indicate P < 0!05 as compared to CKD stage 1, 2, 3 or 4.
© 2013 John Wiley & Sons Ltd
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addition, patients with pre-existing CVD, that is coronary heart
disease, chronic heart failure, stroke or peripheral arterial
disease, had significantly higher FGF-21 concentrations (711!1
[1693!6] ng/l) as compared to subjects without CVD (400!9
[941!3] ng/l) (P < 0!001).
Univariate correlations. Circulating FGF-21 was significantly and
positively associated with age, WHR, WHtR, serum creatinine,
TG, hsCRP, hsIL-6, leptin and adiponectin (Table 2). In
contrast, FGF-21 serum concentrations in this population were
significantly and negatively correlated with DBP, eGFR, FG,
cholesterol, HDL cholesterol and LDL cholesterol (Table 2).
Multivariate regression analysis. After adjustment for age and
gender, multivariate regression analysis of study population 1
revealed that serum FGF-21 levels remained strongly and
negatively associated with eGFR independent of DBP, WHR,
TG, HDL cholesterol, LDL cholesterol, hsIL-6 and adiponectin
(Table 2). Furthermore, circulating FGF-21 remained negatively
and independently associated with LDL cholesterol (Table 2).
Moreover, an independent and positive association was observed
between FGF-21 on one hand and WHR, TG and hsIL-6 on the
other hand (Table 2). In addition, results were virtually identical
when statin treatment or pre-existing CVD was included as
additional covariates in the multivariate model (data not
shown). It is interesting to note that statin treatment but not
pre-existing CVD was an independent predictor of circulating
FGF-21 (data not shown). Furthermore, WHtR and hsCRP were
significant and positive predictors of circulating FGF-21 when
included in the model instead of WHR and hsIL-6, respectively
(data not shown).
Study population 2
FGF-21 serum levels are increased in patients after unilateral
partial or total nephrectomy. Table 3 summarizes baseline
characteristics of study population 2, as well as laboratory
parameters before and after nephrectomy. FGF-21 serum levels
were significantly increased in patients after unilateral partial or
total nephrectomy (325!0 [984!0] ng/l) as compared to
presurgical concentrations (255!5 [243!0] ng/l) (P < 0!001)
(Table 3). Furthermore, creatinine hsCRP and hsIL-6 were
Table 2. Univariate correlations and multivariate regression analysis with





r P ß P
Age (years) 0!116 0!010* 0!032 0!296
Gender – – 0!013 0!701
BMI (kg/m2) 0!029 0!517 – –
SBP (mmHg) "0!003 0!950 – –
DBP (mmHg) "0!172 <0!001* "0!018 0!546
WHR 0!314 <0!001* 0!153 <0!001†
WHtR 0!247 <0!001* – –
Creatinine (lmol/l) 0!719 <0!001* – –
eGFR (ml/min/1!73 m2) "0!727 <0!001* "0!491 <0!001†
FG (mmol/l) "0!107 0!018* – –
FI (pmol/l) "0!032 0!476 – –
HOMA-IR "0!057 0!206 – –
TG (mmol/l) 0!291 <0!001* 0!193 <0!001†
Cholesterol (mmol/l) "0!244 <0!001* – –
HDL cholesterol (mmol/l) "0!340 <0!001* 0!026 0!525
LDL cholesterol (mmol/l) "0!298 <0!001* "0!084 0!009†
hsCRP (mg/l) 0!322 <0!001*
hsIL-6 (ng/l) 0!564 <0!001* 0!210 <0!001†
Leptin (lg/l) 0!124 0!006* – –
Adiponectin (mg/l) 0!247 <0!001* 0!065 0!088
Multivariate regression analysis of FGF-21 (dependent variable) adjusted
for age and gender, as well as DBP, WHR, eGFR, TG, HDL cholesterol,
LDL cholesterol, hsIL-6 and adiponectin. Non-normally distributed
variables were logarithmically transformed prior to multivariate testing.
r- and P-values, as well as standardized ß-coefficients and P-values, are
given. Abbreviations are indicated in Table 1. *indicates significant
correlation as assessed by Spearman’s rank correlation method. † indi-
cates significant correlation in multivariate analysis.
Table 3. Baseline characteristics of study population 2 and serum
parameters before and after renal surgery
Baseline characteristics
N 32
Age (years) 63!0 (12!8)
Gender (m/f) 26/6
Diabetes (%) 6 (19)
BMI (kg/m2) 26!2 (4!9)
SBP (mmHg) 130 (13)







FGF-21 255!5 (243!0) 325!0 (984!0) <0!001*
Creatinine (lmol/l) 86 (33) 96 (44) 0!001*
eGFR (ml/min/1!73 m2) 80!1 (20!4) 63!4 (31!9) 0!001*
FG (mmol/l) 5!5 (1!2) 4!8 (3!6) 0!160
FI (pmol/l) 27!1 (40!6) 34!3 (42!0) 0!062
HOMA-IR 0!9 (1!4) 1!1 (2!4) 0!190
TG (mmol/l) 1!59 (0!74) 1!16 (0!51) <0!001*
Cholesterol (mmol/l) 5!1 (1!4) 4!2 (1!0) <0!001*
HDL cholesterol (mmol/l) 1!1 (0!5) 1!0 (0!4) 0!037*
LDL cholesterol (mmol/l) 3!4 (1!4) 2!6 (1!0) <0!001*
hsCRP (mg/l) 2!0 (8!4) 34!9 (44!8) <0!001*
hsIL-6 (ng/l) 1!4 (2!4) 12!0 (6!7) <0!001*
Leptin (lg/l) 3!4 (5!8) 3!0 (5!8) 0!903
Adiponectin (mg/l) 5!8 (5!4) 5!0 (3!0) <0!001*
Abbreviations are indicated in Table 1. Values for median (interquartile
range) or total number (percentage) are shown. * indicates P < 0!05 as
compared to presurgical values as assessed by Wilcoxon signed-rank test.
© 2013 John Wiley & Sons Ltd
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significantly increased in patients after renal surgery, whereas
eGFR, TG, cholesterol, HDL cholesterol, LDL cholesterol and
adiponectin decreased significantly (Table 3).
Univariate correlations. Relative changes (postsurgical-to-
presurgical ratios) in FGF-21 levels were positively and signif
icantly correlated with creatinine (ratio) (Table 4). Furthermore,
eGFR (ratio) was negatively and significantly associated with
FGF-21 (ratio) (Table 4).
Multivariate regression analysis. Even after adjustment for age
and gender, FGF-21 (ratio) remained positively associated with
creatinine (ratio) in multivariate regression analysis (Table 4). In
addition, results were virtually the same when hsCRP or hsIL-6
were included as markers of inflammation in the multivariate
model (data not shown).
Discussion
In the present study, we demonstrate that FGF-21 levels increase
with deteriorating renal function in a large (n = 499) cohort
covering the whole spectrum of CKD stages (study population
1) for the first time. Furthermore, renal function is the strongest
independent predictor of FGF-21 in this cohort. Moreover, we
show that the adipokine is significantly and acutely upregulated
in patients after unilateral partial or total nephrectomy (study
population 2), a model for AKD.13,14 Interestingly, relative
changes of FGF-21 (postsurgical-to-presurgical ratio) are posi-
tively and independently associated with relative changes in cre-
atinine (postsurgical-to-presurgical ratio) in this cohort. These
findings support the hypothesis that renal excretion is a major
route for eliminating FGF-21 from circulation. It needs to be
pointed out that median time at blood sampling is not the same
for the presurgical and postsurgical measurements. Therefore, an
effect of circadian rhythm on our results cannot be excluded
with certainty; however, FGF-21 concentrations at both time
points are similar according to evidence published by Yu et al.20
Furthermore, circulating FGF-21 does not appear to be dialyz-
able as it is significantly higher after as compared to before
haemodialysis (data not shown).
Our findings suggest that markers of renal function, for exam-
ple creatinine or eGFR, should be included in all studies on
FGF-21 physiology. In agreement with our present findings, we6
and others7 have recently shown upregulation of circulating
FGF-21 in end-stage renal disease. Furthermore, Lin et al.8 dem-
onstrate significantly increased FGF-21 levels in patients with
severe CKD as compared to mild CKD and controls. Animal
studies are necessary to elucidate which mechanisms contribute
to renal elimination of FGF-21 and to determine the physiologi-
cal relevance of increased FGF-21 levels in acute and chronic
renal dysfunction.
Animal experiments demonstrate convincingly that FGF-21 is
an insulin-sensitizing and lipid-lowering adipokine which
increases energy expenditure.3 Thus, Sarruf et al.3 have recently
shown that intracerebroventricular administration of FGF-21 in
obese rats results in improved hepatic insulin sensitivity through
suppression of hepatic glucose production and gluconeogenic
gene expression. In agreement with these findings, Kharitonen-
kov et al.2 reveal that FGF-21 transgenic mice are resistant to
diet-induced obesity. Most interestingly, FGF-21 increases adipo-
nectin secretion in rodents in a very recent paper by Holland
et al.21 In more detail, administration of FGF-21 to obese wild-
type mice results in extensive weight loss and improved glucose
homeostasis.21 In contrast, these beneficial effects are not
observed in obese adiponectin knockout mice suggesting adipo-
nectin-dependent FGF-21 action in rodents.21 In our study pop-
ulation 1, FGF-21 shows a positive correlation with adiponectin
in univariate analysis and a trend towards an independent posi-
tive association in multivariate analysis supporting the hypothe-
sis that upregulation of adiponectin is FGF-21-mediated.
Furthermore, administration of FGF-21 in diabetic primates
results in a significant decline of fasting plasma glucose, as well
as decreased TG and LDL cholesterol levels.22 Moreover, Coskun
et al.23 show convincingly that FGF-21-treated obese mice exhi-
bit increased energy expenditure, fat utilization and lipid excre-
tion. Taking these findings into consideration, it is tempting to
speculate that increased circulating FGF-21 in acute and chronic
Table 4. Univariate correlations with relative changes in FGF-21
(postsurgical-to-presurgical ratio) before and after renal surgery and





r P ß P
Age (years) !0"139 0"448 !0"354 0"027†
Gender – – 0"046 0"762
BMI (kg/m2) 0"010 0"957 – –
SBP (mmHg) !0"023 0"906 – –
DBP (mmHg) !0"293 0"123 – –
WHR !0"023 0"905 – –
WHtR !0"086 0"651 – –
Time interval between
blood samplings (h)
0"165 0"374 – –
Creatinine (ratio) 0"575 0"001* 0"623 <0"001†
eGFR (ratio) !0"547 0"001* – –
FG (ratio) !0"280 0"121 – –
FI (ratio) !0"046 0"803 – –
HOMA-IR (ratio) !0"127 0"488 – –
TG (ratio) !0"168 0"358 – –
Cholesterol (ratio) 0"129 0"482 – –
HDL cholesterol (ratio) 0"103 0"575 – –
LDL cholesterol (ratio) 0"104 0"571 – –
hsCRP (ratio) !0"109 0"554 – –
hsIL-6 (ratio) 0"008 0"965 – –
Leptin (ratio) !0"008 0"964 – –
Adiponectin (ratio) 0"000 0"998 – –
Multivariate regression analysis of FGF-21 (ratio, dependent variable)
and age, gender, as well as creatinine (ratio) in all patients. Non-nor-
mally distributed variables were logarithmically transformed prior to
multivariate testing. r- and P-values, as well as standardized ß-coeffi-
cients and P-values, are given. Abbreviations are indicated in Table 1.
* indicates significant correlation as assessed by Spearman’s rank correla-
tion method. † indicates significant correlation in multivariate analysis.
© 2013 John Wiley & Sons Ltd
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renal dysfunction might limit the adverse metabolic and vascular
effects of the disease. Alternatively, FGF-21 resistance might be
present in acute and chronic renal dysfunction similar to insulin
resistance seen in obesity.24 It is interesting to note in this con-
text that FGF-21 resistance has already been described in obes-
ity.25 In more detail, Fisher et al.25 show convincingly that FGF-
21 mRNA expression increases in the liver and in white adipose
tissue of obese mice. Furthermore, activation of the FGF-21 sig-
nalling pathways and FGF-21 mediated early gene transcription
is impaired in obese mice.25 Clearly, more mechanistic studies
are needed to better elucidate the physiological role of increased
FGF-21 in acute and chronic kidney dysfunction.
In accordance with results obtained in obese rodents, we show
a strong, positive and independent correlation between serum
FGF-21 levels and WHR as a marker of adverse fat distribution in
study population 1. This is in accordance with a study by Zhang
et al.26 They reveal a positive association between FGF-21 levels
and WHR even after adjustment for age and BMI in their study
comprising 232 subjects.26 Similarly, FGF-21 is positively and
independently correlated with WHtR in the present study which
is an alternative marker for adverse body fat distribution. Interest-
ingly, FGF-21 is not significantly associated with BMI and is not
different between overweight/obese patients as compared to lean
subjects. Because WHR and WHtR better reflect adverse body fat
distribution as compared to BMI,27,28 it is tempting to speculate
that an accumulation of visceral fat rather than increased body fat
mass leads to a FGF-21 resistant state. Clearly, future studies
are needed to determine the pathophysiological significance of
FGF-21 upregulation/resistance in metabolic diseases.
In study population 1, FGF-21 correlates positively and inde-
pendently with further markers of the MetS including TG and
hsCRP similar to other reports.29,30 In contrast to other stud-
ies,29,31 FGF-21 does not correlate with measures of insulin resis-
tance including FI and HOMA-IR. Interestingly, LDL cholesterol
correlates paradoxically and negatively with circulating FGF-21
in study population 1 in multivariate analyses. These data are in
accordance with a recent study from our group in pregnant
women.32 It is interesting to note in this context that FGF-21
increases LDL-receptor expression in cultured human hepato-
cytes leading to an enhanced lipoprotein uptake.33 However, it
needs to be pointed out that other data suggest a positive associ-
ation between LDL cholesterol and FGF-21 levels in contrast to
our findings.34 Differences in patient characteristics with regard
to age, gender, renal function, ethnicity and phenotyping might
well explain the different findings.
In contrast to FGF-21, adiponectin levels significantly decline
after unilateral nephrectomy. Decreased adiponectin levels after
surgery are paradoxical as its secretion is stimulated by FGF-
2121, and its renal clearance is likely to be reduced postopera-
tively.35 Clearly, the causes for this unexpected regulation need
to be elucidated in future studies.
There are some limitations of the study that need to be
emphasized. First, a cross-sectional design is used for study pop-
ulation 1, and therefore, causality cannot be established. Second,
the sample size of study population 2 is rather small, and it
is quite possible that various nonsignificant associations in
multivariate analyses would have become statistically significant
if larger samples were studied. Third, we cannot exclude the
possibility that confounding factors that influence circulating
FGF-21 have not been considered. Fourth, no information is
available in the present study concerning specific FGF receptors
and b-klotho in target tissues through which biologically active
FGF-21 acts.
Taken together, we demonstrate for the first time that circu-
lating FGF-21 is increased in both CKD and AKD. Our results
support the hypothesis that renal excretion is a major route to
eliminate FGF-21 from circulation. The pathophysiological sig-
nificance of these findings needs to be elucidated in more detail.
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The prevalence of the Metabolic Syndrome (MetS) has been increasing globally for the past 
decades and the prevalence in Germany is above 20 %. The MetS is associated with an 
increased risk for cardiovascular morbidity and mortality. According to the NCEP definition, 
key aspects of the MetS include increases in serum lipids, elevated blood pressure, 
hyperglycemia, as well as central obesity. Out of these components, central obesity shows the 
strongest association with the MetS and weight loss therapy improves all MetS aspects, as 
well as its comorbidities. The development of central obesity usually occurs alongside with an 
increase in central adipose tissue mass. Adipose tissue functions as a complex endocrine 
organ and endocrine networks are dysregulated in obese patients. Adipose tissue produces a 
multitude of proteins – so-called adipokines – with various effects on human metabolism. 
These adipokines provide a potential link between body mass and the occurrence of metabolic 
disturbances. 
In this context, FGF-21, a novel adipokine with beneficial effects on glucose and lipid profile 
in rodents, has been subject to thorough investigation. FGF-21 stimulates glucose uptake in 
preadipocytes independent from insulin. Furthermore, administration of the adipokine reduces 
body weight and improves insulin sensitivity in rodents and primates. In humans, FGF-21 
levels are dysregulated in different metabolic disease states. Thus, FGF-21 concentrations are 
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elevated in patients with T2DM. In accordance with these findings, obese patients exhibit 
increased levels of the adipokine and the number of manifested MetS components predicts 
FGF-21 concentrations. A FGF-21-resistant state has been implied to be partially accountable 
for these findings. Despite extensive studies on FGF-21 regulation in human metabolic 
disease, data on FGF-21 elimination were rather limited.  
Therefore, the relation between the adipokine and human renal function in patients with 
chronic kidney disease (study population 1) and acute renal impairment (study population 2) 
has been investigated in the context of this dissertation. The adipokine was quantified in 
venous blood samples by commercial enzyme linked immunosorbent assay and correlated to 
anthropometric and biochemical markers of renal function, glucose and lipid homeostasis, as 
well as inflammation.  
Study population 1 (n = 499) was divided into 5 groups representing CKD stages 1 to 5 
according to the KDOQI criteria. Median FGF-21 serum levels progressively increased from 
stage 1 to 5 (1: 86.4 ng/l; 2: 206.4 ng/l; 3: 289.8 ng/l; 4: 591.3 ng/l; 5: 1918.1 ng/l) while renal 
function assessed as eGFR progressively declined. In multivariate analysis, eGFR remained 
the strongest predictor for FGF-21 levels (p < 0.001).  
In study population 2 (n = 32) FGF-21 levels were quantified in patients undergoing unilateral 
partial or total nephrectomy shortly before surgery, and again within 30 hours after surgery. 
Median FGF-21 levels significantly increased after (325.0 ng/l) as compared to before surgery 
(255.5 ng/l; p < 0.001). Furthermore, relative changes of FGF-21 were independently and 
positively predicted by relative changes of creatinine in this cohort (p < 0.001). 
Taken together, these results further support a strong relation between the adipokine FGF-21 
and chronic renal dysfunction. Furthermore, first data regarding increased FGF-21 levels in 
acute kidney injury are presented. Our results are in accordance with the hypothesis that renal 
elimination of the adipokine is a major contributor to FGF-21 physiology. Animal studies are 
needed in order to further elucidate the role of elevated FGF-21 levels in kidney dysfunction 
and to define the extent to which serum FGF-21 elevation contributes to kidney disease 
comorbidities. 
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A. Abbreviations 
 
CCRL2  ............................................................................................. Chemokine receptor-like 2 
CKD ....................................................................................................... Chronic Kidney disease 
CMKLR1  .......................................................................................... Chemokine receptor-like 1 
CRP  ................................................................................................................ C-reactive protein 
CVD  ...................................................................................................... Cardiovascular disease 
eGFR .................................................................................. Estimated glomerular filtration rate 
ESRD  ..................................................................................................... End-stage renal disease 
FGF-21 ........................................................................................... Fibroblast growth factor -21 
GLUT-1  ................................................................................................... Glucose transporter-1 
GPR1  ............................................................................................ G protein-coupled receptor 1 
HDL  ...................................................................................................... High density lipoprotein 
hs  ........................................................................................................................ High sensitivity  
IL-6  ......................................................................................................................... Interleukin-6 
KDOQI ....................................................................... Kidney disease quality outcome initiative 
LDL  ....................................................................................................... Low density lipoprotein  
MetS ............................................................................................................ Metabolic Syndrome 
mRNA  ............................................................................................. Messenger ribonucleic acid 
NCEP ..................................................................... National Cholesterol Education Programme 
NPY ..................................................................................................................... Neuropeptide Y 
ob gene ...................................................................................................................... Obese gene 
T2DM .................................................................................................... Type 2 diabetes mellitus 
TNF .......................................................................................................... Tumor necrosis factor 
WHR  ............................................................................................................... Waist-to-hip ratio 
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